Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design.
To explore the role of the National Institutes of Health (NIH) in innovative drug development and its impact on patient access, the Board on Health Care Services and the Board on Health Sciences Policy of the National Academies jointly ...
... per month for this medication . As of 2016 , Celgene's cancer drug Revlimid costs $ 150,000 per year . In 2014 , Gilead Sciences was called before Congress to explain its $ 1,000 - a - day price tag on the hepatitis C medication Sovaldi ...
... cost more than $ 120 a month . If you think that's a lot , hold on to your hat . People with cancer or rare medical ... per month . Avastin ( bevacizumab ) for colorectal cancer can cost $ 4,400 per month . Revlimid ( lenalidomide ) ...
... Revlimid (a modern derivative of thalidomide, a drug first used in the 1950s in Europe), which cost him $250 per month out of pocket. In contrast, the median out-of- pocket cost for Revlimid for Medicare beneficiaries was $15,000 per ...
THE ESSENTIAL WORK IN TRAVEL MEDICINE -- NOW COMPLETELY UPDATED FOR 2018 As unprecedented numbers of travelers cross international borders each day, the need for up-to-date, practical information about the health challenges posed by travel ...
Rare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging.
... Per Share Data ( S ) 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 ... Month EPS $ 0.59 S & P Oper . EPS 2010E 2.40 Yield ( % ) Nil Trailing 12 ... Revlimid , the company currently depends on two products in the same markets ...